Form 4 for TXG 10x Genomics, Inc.
Accepted 2026-01-07 00:00:00 ET · period of report 2026-01-05 · accession 0001610717-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-07 | 2026-01-05 | TXG | Saxonov Serge | CEO, Dir | M - OptEx | $1.20 | +50.0K | 1.07M | +5% | +$60.0K |
| DM | 2026-01-07 | 2026-01-05 | TXG | Saxonov Serge | CEO, Dir | M - OptEx | $0.00 | -50.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-01-05 | M | A | 50,000 | $1.20 | 1,071,556 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2026-01-05 | M | D | 32,537 | $0.00 | 173,600 | D | $1.20 · — to 2027-10-18 | 32,537 Class A Common Stock | (F4) All of the shares subject to the option are fully vested and exercisable as of the date hereof. |
| 3 | Derivative | Stock Option (right to buy) | 2026-01-05 | M | D | 17,463 | $0.00 | 0 | D | $1.20 · — to 2027-10-18 | 17,463 Class A Common Stock | (F4) All of the shares subject to the option are fully vested and exercisable as of the date hereof. |